# AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

Source: https://onco.cc/trials/nct07215585/  
OnCo record `nct07215585` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing AZD0486 in diffuse large B-cell lymphoma, now recruiting.

## Summary

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL is a phase 3 interventional study registered as NCT07215585, led by AstraZeneca, and recruiting on the registry. Official title: A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 Followed by AZD0486 Versus R-mini-CHOP x6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2). Planned enrolment is 420 participants (estimated). The study started in 2025-11-11 and primary completion is expected in 2030-06-10. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: SOUNDTRACK-D2
- Tags: ctgov-ingest
- Registry id: NCT07215585
- Phase: 3
- Setting: A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 Followed by AZD0486 Versus R-mini-CHOP x6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)
- Sponsor: AstraZeneca
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT07215585: https://clinicaltrials.gov/study/NCT07215585

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [AZD0486](https://onco.cc/drugs/azd0486/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07215585.json